Schering-Plough - Investor Relations - Shareholder Information

	Internet Proxy Voting

	Internet Proxy Voting If you are a shareholder, you may vote your proxy by selecting the appropriate link below: Shareholder of Record - Select this link if you hold your stock in your own name through The Bank of New York. Street Name Shareholder - Select this link if you hold your stock in the name of a bank, broker, or other holder of record.




	Click here for more information about COPPERTONE.

•	World Headquarters: 2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530

•	Chairman and CEO: Fred Hassan

•	Number of employees: 55,000


•	Net sales (2007): $12.7 billion


•	Business operations in more than: 140 countries

•	Largest-selling products: *VYTORIN, ZETIA, REMICADE, NASONEX.*

•	R&D investment (2007): $2.9 billion

•	Areas of research: cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health *VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.

Internet Proxy Voting